Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with ...

Denmark-based multinational pharmaceutical company Novo Nordisk will be making available in the Philippines within this year Wegovy, its approved weight loss treatment for ...

Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in ... CagriSema achieved a weight loss of 15.7% after 68 weeks ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...